Therefore, our study not only illustrates a mechanism underlying abrogation of Vimentin degradation during active AKT-driven LAD progression but also provides a foundation for developing Vimentin stability as a diagnostic marker or a therapeutic target for anti-cancer strategy. The gene discussed is AKT1; the disease is cancer.